Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Aug 15;110(4):1178-83.
doi: 10.1182/blood-2007-01-066043. Epub 2007 Apr 17.
Affiliations
- PMID: 17440049
- DOI: 10.1182/blood-2007-01-066043
Free article
Randomized Controlled Trial
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Monica Galli et al. Blood. 2007.
Free article
Abstract
To assess the clinical significance of lupus anticoagulants (LAs) and antiphospholipid antibodies (aPLs) toward thrombosis and abortions, we measured them in 112 patients whose samples were available at enrollment in the warfarin in the antiphospholipid syndrome (WAPS) study. Enzyme-linked immunosorbent assay (ELISA) and coagulation test values in the highest and lowest tertiles were compared. When considered separately, IgG antibodies to beta2-glycoprotein I (abeta2GPI) and prothrombin (aPT) were associated with anamnestic arterial and venous thrombosis, respectively, and those to annexin AV (aAnAV) with abortions. IgM antibodies to protein S and the lupus ratio of the dilute prothrombin time were associated with prospective thrombosis. No other association for IgM antibodies was seen. LA-positive patients who carried abeta2GPI antibodies were at risk of anamnestic arterial and total thrombosis and aPT antibodies to that of anamnestic venous and total thrombosis. LA-positive patients who carried IgG abeta2GPI and aAnAV antibodies were at risk for both anamnestic abortion and prospective thrombosis. Overall, these data support the inclusion of abeta2GPI antibodies in and suggest the removal of anticardiolipin antibodies from the laboratory criteria of the antiphospholipid syndrome. They also suggest that the measurement of aPT and aAnAV antibodies is useful in some selected situations and that there is little role for IgM antibody detection.
Similar articles
- Antibody profiles for the diagnosis of antiphospholipid syndrome.
Pengo V, Biasiolo A, Pegoraro C, Cucchini U, Noventa F, Iliceto S. Pengo V, et al. Thromb Haemost. 2005 Jun;93(6):1147-52. doi: 10.1160/TH04-12-0839. Thromb Haemost. 2005. PMID: 15968401 - Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-β2glycoprotein I antibody detection assays.
Chayoua W, Kelchtermans H, Moore GW, Musiał J, Wahl D, de Laat B, Devreese KMJ. Chayoua W, et al. J Thromb Haemost. 2018 Oct;16(10):2016-2023. doi: 10.1111/jth.14261. Epub 2018 Aug 24. J Thromb Haemost. 2018. PMID: 30079628 - The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR. Bertolaccini ML, et al. J Rheumatol. 2001 Dec;28(12):2637-43. J Rheumatol. 2001. PMID: 11764209 - Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome.
Galli M. Galli M. Semin Thromb Hemost. 2008 Jun;34(4):329-34. doi: 10.1055/s-0028-1085474. Epub 2008 Sep 23. Semin Thromb Hemost. 2008. PMID: 18814065 Review. - IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis.
Kelchtermans H, Pelkmans L, de Laat B, Devreese KM. Kelchtermans H, et al. J Thromb Haemost. 2016 Aug;14(8):1530-48. doi: 10.1111/jth.13379. Epub 2016 Aug 11. J Thromb Haemost. 2016. PMID: 27279342 Review.
Cited by
- Complement biomarkers in the antiphospholipid syndrome - Approaches to quantification and implications for clinical management.
Cole MA, Gerber GF, Chaturvedi S. Cole MA, et al. Clin Immunol. 2023 Dec;257:109828. doi: 10.1016/j.clim.2023.109828. Epub 2023 Oct 31. Clin Immunol. 2023. PMID: 37913840 Review. - Laboratory Testing for Non-criteria Antiphospholipid Antibodies: Anti-phosphatidylserine/Prothrombin Antibodies (aPS/PT).
Devreese KMJ. Devreese KMJ. Methods Mol Biol. 2023;2663:315-327. doi: 10.1007/978-1-0716-3175-1_20. Methods Mol Biol. 2023. PMID: 37204720 - A Comprehensive Review of Risk Factors for Venous Thromboembolism: From Epidemiology to Pathophysiology.
Pastori D, Cormaci VM, Marucci S, Franchino G, Del Sole F, Capozza A, Fallarino A, Corso C, Valeriani E, Menichelli D, Pignatelli P. Pastori D, et al. Int J Mol Sci. 2023 Feb 5;24(4):3169. doi: 10.3390/ijms24043169. Int J Mol Sci. 2023. PMID: 36834580 Free PMC article. Review. - Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Weitz JI, Szekanecz Z, Charles-Schoeman C, Vranic I, Sahin B, Paciga SA, Wang Z, Hyde C, Martin DA. Weitz JI, et al. RMD Open. 2022 Nov;8(2):e002571. doi: 10.1136/rmdopen-2022-002571. RMD Open. 2022. PMID: 36323490 Free PMC article. Clinical Trial. - Emerging Therapies in Antiphospholipid Syndrome.
Hubben A, McCrae KR. Hubben A, et al. Transfus Med Rev. 2022 Oct;36(4):195-203. doi: 10.1016/j.tmrv.2022.09.002. Epub 2022 Sep 24. Transfus Med Rev. 2022. PMID: 36272841 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources